12 November 2024 in European Journal of Neurology
Background and purpose: Paramagnetic rim lesions (PRLs) are chronic active lesions associated with a severe disease course in multiple sclerosis (MS). This study was undertaken to investigate an association between retinal layer thinning (annualized loss of peripapillary retinal nerve fiber layer [aLpRNFL] and ganglion cell–inner plexiform layer [aLGCIPL]) and PRLs in patients with MS (pwMS).Methods: In this study, pwMS with brain magnetic resonance imaging and ≥2 optical coherence tomography scans were included. Cox proportional hazard regression models were performed using progression independent of relapse activity (PIRA) as the dependent variable, and aLpRNFL, aLGCIPL, or the number of PRLs as independent variables, adjusted for covariates.Results: We analyzed data from 97 pwMS (mean age = 35.2 years [SD = 9.9], 71.1% female, median disease duration = 2.3 years [interquartile range = 0.9–9.0]). The number of PRLs was associated with aLpRNFL and aLGCIPL. PIRA was observed in 18 (18.6%) pwMS, with aLpRNFL (hazard ratio [HR] = 1.44 per %/year), aLGCIPL (HR = 1.61 per %/year), and the number of PRLs (HR = 1.24 per PRL) being associated with increased risk of PIRA.Conclusions: The number of PRLs is associated with inner retinal layer thinning and increased risk of PIRA. A combination of PRLs and retinal layer thinning could serve as a surrogate for pwMS at highest risk of disability progression.
16 December 2024 in European Journal of Neurology
Objective: To investigate the impact of transition interval length when switching from natalizumab (NTZ) to anti‐CD20 monoclonal antibodies (antiCD20) on recurrent disease activity and safety in relapsing multiple sclerosis (RMS).Methods: Aggregating data from 8 MS centres in Austria, Switzerland, and Germany, we included RMS patients who (i) continuously received NTZ for ≥3 months, (ii) were switched to antiCD20, and (iii) had ≥12 months follow‐up after switch. The primary endpoint was occurrence of relapse after switch, secondary endpoints included severe infections (CTCAE grade ≥3).Results: Overall, 139 RMS patients were included (70.5% females, mean age at switch 38.8 years [SD 9.7], mean disease duration at switch 11.3 years [SD 6.2], median duration on NTZ 4.4 years [range: 0.3–16.4], median transition interval 58 days [0–180]). Relapse occurred in 18 patients (12.9%) after NTZ discontinuation. Of those, 11 (61.1%) patients relapsed during the transition interval. No patient with a transition interval below 30 days experienced a relapse, compared to 11.1% and 16.1% with transition intervals of 30–44 days and ≥ 45 days, respectively. In multivariable Cox regression, a transition interval ≥ 45 days predicted a 4.73‐fold increased risk of relapse. Over approximately 4 years of follow‐up, six severe infections were reported without any noticeable effect of transition interval length. No PML occurred.Conclusions: Switching from NTZ to antiCD20 is generally both effective and safe. Keeping the transition interval below 30 days provides the optimal balance between preventing recurrent disease activity and ensuring safety.
5 April 2025 in European Journal of Neurology
Introduction: Lumbar puncture (LP) is a routine clinical procedure and, in some cases, is repeatedly performed for diagnostic or therapeutic reasons. The impact of repeated LP on cerebrospinal fluid (CSF) findings is not clear.Objective: To investigate whether repeated LP is associated with reactive pleocytosis and disruption of blood–CSF barrier function and to determine the role of interval between repeated LP.Methods: Patients with non‐inflammatory neurological disease (NIND) and at least two consecutive LP were included. Longitudinal changes in CSF white blood cell count (WBC), CSF total protein (TP), and CSF/serum albumin quotient (Qalb) were assessed depending on the time interval between the LP.Results: A total of 73 patients with a median age of 35 years (25th–75th percentile: 25–45) and a female predominance of 75% had second LP after 6 (3–19) days. Twenty (27%) patients developed pleocytosis with an increase of WBC count to 8/μl (6–15) with a maximum of 30/μl. Patients with pleocytosis had the follow‐up LP significantly earlier than patients without pleocytosis, 3.5 (3–7) versus 7 (3–28) days. The majority of patients (90%) with CSF pleocytosis had the second LP within 10 days. Further repeated LP in a subgroup of patients revealed similar findings. CSF TP and Qalb slightly increased in patients with pleocytosis.Conclusion: Mild “reactive” CSF pleocytosis occurred in approximately one‐third of patients after repeated LP, mostly when performed within 10 days.
27 November 2024 in European Journal of Neurology
Background and purpose: Autoimmune screening panels (ASPs) are often ordered as a part of the diagnostic workup in people with suspected multiple sclerosis (MS). However, data on the significance of ASP seropositivity in MS are scarce. This study aimed to investigate whether routine implementation of ASPs is viable in MS diagnostic workup.Methods: In this retrospective study, we included patients from the Vienna Multiple Sclerosis Database who were diagnosed with MS according to current McDonald criteria between 2014 and 2021 and had an ASP performed.Results: We analyzed 212 patients (mean age at serology = 30.4 [SD = 8.5] years, 67% female). Red flag symptoms for presence of systemic autoimmune disease were reported by 5.6% of patients during initial evaluation (sicca syndrome [n = 5], joint pain [n = 4], dermatitis [n = 4]). Complement levels (C3c and C4) were below the lower reference level in 26 of 134 (19.4%) and three of 134 (2.2%), respectively. Antinuclear antibodies (ANAs) were positive in 24 of 210 (11.4%), with 18 (8.6%), five (2.4%), and one (0.5%) having mildly, moderately, and strongly positive ANA titers. Extractable nuclear antibody subsets were positive in 10 of 211 (4.7%) patients. ASPs led to the diagnosis of mixed connective tissue disease (n = 1), psoriatic arthritis (n = 1), and Sjögren syndrome (n = 2; positive predictive value [PPV] = 4.9%, negative predictive value [NPV] = 99.3%). Among patients presenting with red flag symptoms, ASPs had better overall test performance (PPV = 100%, NPV = 88.9%).Conclusions: The rate of ASP seropositivity in MS is low and within the range of the general population. Performance of ASPs without clinical suspicion of systemic autoimmune disease seems unwarranted.
17 December 2025 in European Journal of Neurology
Background: Cerebrospinal fluid (CSF) analysis is key to diagnosing multiple sclerosis (MS). In particular, the presence of CSF‐specific oligoclonal bands (OCB) is examined alongside differential diagnostic aspects. This study aims to investigate the diagnostic value of OCB in MS compared to other neurological disorders. Methods: Patients who presented to the Department of Neurology of the Medical University of Vienna between January 1, 2004 and December 31, 2020, due to neurological complaints and underwent lumbar puncture (LP) for diagnostic purposes were included in this retrospective analysis. Exclusion criteria were incomplete laboratory data and/or a missing final diagnosis. Results: Of 5744 patients who underwent LP, 5225 were available for analysis. Of these, 745 (14.3%) were diagnosed with MS, whereby CSF‐specific OCB showed a sensitivity of 92.8% and a specificity of 90.4%. While the positive predictive value (PPV) was merely 61.5%, the negative predictive value (NPV) yielded 98.7%. In comparison, OCB displayed low sensitivity rates for most other neurological disease groups. Of note, neuroborreliosis ( n = 66) had a relatively high OCB positive rate of 70%, followed by CNS human immunodeficiency virus infections ( n = 32) with 62.5%. Conclusions: CSF‐specific OCB have a high sensitivity and specificity and a very high NPV for diagnosing MS. However, the PPV was lower in this cohort. These findings must be carefully considered when diagnosing MS and interpreting OCB, especially in the context of differential diagnostic workup.
28 May 2026 in Annals of Neurology
Objectives: The pathophysiology of idiopathic intracranial hypertension (IIH) is poorly understood and disease‐specific biomarkers are lacking. We aimed to shed light on IIH pathophysiology and identify disease‐specific biomarkers. Methods: This prospective cross‐sectional cohort study included patients with new‐onset IIH and age‐, body mass index‐, and sex‐matched healthy controls from 2 tertiary Danish Headache Centers (discovery cohort). Liquid chromatography coupled to tandem mass spectrometry analysis was used to measure reproducible proteomic profiles for paired serum and cerebrospinal fluid (CSF) samples. Results were validated using 3 validation cohorts comprising patients with IIH (pwIIH), cerebral sinus venous thrombosis (pwCSVT), and normal pressure hydrocephalus (pwNPH). Results: We included 53 pwIIH and 35 controls. PwIIH presented with papilledema and increased median lumbar puncture opening pressure (interquartile range [IQR]) (38.0 [33–46] vs 19.0 [17.0–23.0] cmH 2 O; p < 0.001) compared to controls. Machine learning analysis identified 20 IIH‐predicting proteins for serum and CSF segregating pwIIH, but neither pwCSVT nor pwNPH, from controls with areas under the curve (AUC) of 0.84 and 0.92 (pwIIH, discovery cohort), 0.99 and 0.90 (pwIIH, validation cohort 1), 0.63 (plasma; pwCSVT), and 0.67 (CSF; pwNPH), respectively. Serum carbonic anhydrases (CA) 1 and 2 were upregulated and among the most IIH‐predicting proteins as were amyloid precursor protein (APP), S100P, and S100A12. Interpretation: We identified a panel of independently validated IIH‐specific candidate biomarkers. The serum candidate biomarkers pointed toward CA2 driven CSF hypersecretion in IIH providing a possible explanation for the therapeutic efficacy of CA inhibitors. The regulation of markers associated with neuronal impairment (APP, S100P/S100A12) confirmed the non‐benign character of IIH. ANN NEUROL 2026